Northwest Biotherapeutics is focused on developing immunotherapy products to treat cancers more effectively than current treatments and without toxicities of the kind associated with chemotherapies. NWBO’s lead program is a phase 3 trial in newly diagnosed Glioblastoma multiforme (GBM). NWBO also previously received FDA clearance for a phase 3 trial in prostate cancer, and clearance from the FDA for phase 1/2 trials in multiple other cancers. For more information, visit the company’s Web site: http://www.nwbio.com
Let us hear your thoughts below: